Meritus Health said it has expanded its endocrinology services to the city of Frederick. Meritus has a hospital near Hagerstown, in addition to a larger network of other facilities. This addition ...

Panelists discuss how the shift from intravenous (IV) to subcutaneous (SubQ) drug administration is transforming oncology care delivery, highlighting its lasting impact on patient experience ...

CHICAGO — Positive interpretations of randomized phase 3 oncology trials often are based on improvements in unvalidated alternative endpoints, findings presented at ASCO Annual Meeting ...

The fourth International Conference on Advances in Radiation Oncology (ICARO-4) is underway this week at the IAEA headquarters in Vienna, bringing together participants from around the world to ...

In this episode, host Shikha Jain, MD, speaks with Sadie Dobrozsi, MD, about the power of information in personalized oncology care, understanding the impacts of genetic testing and more. Sadie ...

Predictive Oncology expands its AI drug discovery platform to include biomarker discovery and drug repurposing, enhancing precision oncology capabilities.

OmRx Oncology, or “OmRx,” is a biopharmaceutical venture formed around a single clinical-stage asset, OX-4224, an investigational oral checkpoint inhibitor being evaluated for the potential ...

ALX Oncology plans to launch new trials testing evorpacept with trastuzumab in HER2-positive breast cancer and with cetuximab in colorectal cancer, according to a March 5 release.

The Meritus Medical Center PGY-1 Pharmacy Residency program has received accreditation through 2029. The nearly decade-old program recently earned reaccreditation from ASHP, the largest association of ...

Strategies for helping the children of patients with cancer cope with their parent’s disease, treatment, and prognosis.

Texas Oncology partners with Canopy to improve patient outcomes and reduce hospitalizations through electronic feedback management. Canopy's tools have shown success in pilot programs, enhancing ...

BridgeBio Oncology Therapeutics, a company working to advance the field of therapies addressing a validated but elusive group of cancer targets, has reached a deal to go public in a SPAC merger ...